Radioimmunotherapy trials in germ testicular carcinoma: a phase I study

Int J Biol Markers. 1990 Oct-Dec;5(4):188-94. doi: 10.1177/172460089000500404.

Abstract

Two patients with germ cell testicular cancer were submitted to radioimmunotherapy (RIT) by using the monoclonal antibody 131I-radiolabelled (MoAb) H17E2, raised against placental alkaline phosphatase (PLAP). Both patients had been previously treated with repeated chemotherapy regimens assisted by autologous bone marrow transplant (ABMT), that, in the end were unsuccessful, thus necessitating further experimental treatment. RIT was well tolerated and the targeting of multiple neoplastic lesions was satisfactory. Nevertheless, the clinical results of treatment were minimal owing to the extension of the tumour. The data obtained suggest the possibility of applying this form of treatment in patients with minimal residual disease after previous traditional chemotherapy regimens.

Publication types

  • Clinical Trial

MeSH terms

  • Adult
  • Alkaline Phosphatase / immunology
  • Antibodies, Monoclonal / adverse effects
  • Antibodies, Monoclonal / therapeutic use
  • Biomarkers, Tumor / blood
  • Biomarkers, Tumor / immunology
  • Combined Modality Therapy
  • Humans
  • Immunotherapy / adverse effects
  • Iodine Radioisotopes / adverse effects
  • Iodine Radioisotopes / therapeutic use
  • Male
  • Neoplasms, Germ Cell and Embryonal / blood
  • Neoplasms, Germ Cell and Embryonal / radiotherapy
  • Neoplasms, Germ Cell and Embryonal / therapy*
  • Testicular Neoplasms / blood
  • Testicular Neoplasms / radiotherapy
  • Testicular Neoplasms / therapy*

Substances

  • Antibodies, Monoclonal
  • Biomarkers, Tumor
  • Iodine Radioisotopes
  • Alkaline Phosphatase